Abstract
• Integrin may act as an alternative receptor for SARS-CoV-2 and could be implicated in its transmission and pathology. • The spike protein of SARS-CoV-2 acquired a RGD motif known to bind integrins. This motif is absent from other coronaviruses. • The integrin-binding motif is present at the surface of the spike protein, close to the ACE2 receptor-binding region. • Integrin binding may be a promising therapeutics target, and should be tested experimentally.
Highlights
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source
SARS-CoV-2 belongs to the genus Betacoronavirus of the large family of Coronaviridae (“Betacoronavirus ~ ViralZone,” n.d.)
We suggest that SARS-CoV-2 may use integrins as cell receptors in one or more host species, binding to them through a conserved RGD (403–405: Arg-Gly-Asp) motif that is present in the receptor-binding domain of the spike proteins of all SARS-CoV-2 sequences analyzed to date (Fig. 2)
Summary
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. A potential role for integrins in host cell entry by SARS-CoV-2 We suggest that SARS-CoV-2 may use integrins as cell receptors in one or more host species, binding to them through a conserved RGD (403–405: Arg-Gly-Asp) motif that is present in the receptor-binding domain of the spike proteins of all SARS-CoV-2 sequences analyzed to date (Fig. 2).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
